Harbour backs first registrational trials with $75M B+ round

Harbour BioMed raised $75 million in a series B+ round to advance its clinical antibody programs, including three registrational trials planned for this year.

New investors SK Holdings, Greater Bay Area Fund, Efung Capital, Zheshang Venture Capital, Zhejiang University Future Capital and JT New Century and existing investors including Legend Capital, AdvanTech and GIC participated in the financing...